Original Research ARTICLE
The prognostic value of programmed death-ligand 1 in a Chinese cohort with clear cell renal cell carcinoma
- 1Fudan University Shanghai Cancer Center, China
- 2Department of Oncology, Shanghai Medical College, Fudan University, China
- 3Collaborative Innovation Center for Genetics and Development, Fudan University, China
OBJECTIVE: To investigate the association between tumor PD-L1 expression and patient survival to determine whether PD-L1 represents an independent prognostic feature for patients with nonmetastatic clear cell renal cell carcinoma.
PATIENTS AND METHODS: Tissue bank of Fudan University Shanghai Cancer Center was queried to identity tissue samples of patients treated with radical nephrectomy for nonmetastatic sporadic clear cell renal cell carcinoma during the period of 2008 to 2015. Real-time polymerase chain reaction and immunohistochemistry staining was performed to detect the expression level of PD-L1 in paired cancer tissue and paracancerous tissue.
RESULTS: 330 patients were enrolled into this study, with the mean age of 55.0 years at surgery and mean size of 5.2cm. 242 (73.3%) and 88 (26.7%) patients showed high and low expression of PD-L1 mRNA, respectively, while 254 patients had positive PD-L1 immunohistochemistry staining. 292 patients has consistent results for mRNA and protein of PD-L1 based upon these different detection methods. Patients with high PD-L1 expression were more likely to exhibit adverse pathologic features including advanced T stage (P=0.002) and lymph node metastasis (P=0.044). The Kaplan-Meier curves of PFS and OS stratified by PD-L1 expression had statistically significant difference. PD-L1 expression maintained a significant predictive role for PFS and OS in multivariate cox model.
CONCLUSIONS: Our data suggested that PD-L1correlated with prognosis in RCC, and targeting the PD-1/PD-L1 pathway should be considered in the treatment of RCC patients.
Keywords: programmed death–ligand 1, Renal cell carcinoma (RCC) clear cell renal cell carcinoma (CCRCC), Immunohistochemistry, Real-Time Polymerase Chain Reaction, overall survival, Progression-free survival
Received: 12 Feb 2019;
Accepted: 23 Aug 2019.
Copyright: © 2019 Xiao, Zhang, Zhou, Zhang, Dai, Zhu, Shi, Shen, Zhu, Qu, Zhao and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Yuan-yuan Qu, Fudan University Shanghai Cancer Center, Shanghai, China, firstname.lastname@example.org
Dr. Jian-yuan Zhao, Fudan University Shanghai Cancer Center, Shanghai, China, email@example.com
Prof. Ding-wei Ye, Fudan University Shanghai Cancer Center, Shanghai, China, firstname.lastname@example.org